Dr. Ben Hwang, CEO of Profusa, discusses the future of continuous health monitoring through implantable biosensors.

On Technology Vision

Q: What is Profusa’s vision?

Dr. Hwang: Imagine having continuous, real-time insight into your body’s chemistry. Our biosensors make this possible, enabling proactive rather than reactive healthcare. Instead of periodic snapshots from blood tests, you could have comprehensive, longitudinal data about your health.

This could transform how we manage chronic diseases, optimize wellness, and conduct clinical research.

On Applications

Q: What are the key applications?

Dr. Hwang: We see applications across chronic disease management, wellness optimization, and clinical research. Diabetes management is an obvious opportunity given the success of continuous glucose monitors. But our technology could extend to other analytes like lactate, oxygen, and therapeutic drug levels.

For clinical research, continuous monitoring could provide richer data on drug effects and patient responses.

On Healthcare Transformation

Q: How could this change healthcare?

Dr. Hwang: Continuous monitoring enables fundamentally different approaches to care. Instead of treating symptoms after they appear, we could detect deviations from baseline early and intervene proactively. This could improve outcomes while reducing costs.

The shift from episodic to continuous data also enables personalized medicine based on individual physiology rather than population averages.

On Development Progress

Q: Where is the technology today?

Dr. Hwang: We have demonstrated our core technology in clinical studies and are advancing toward commercial applications. Regulatory approval is a key focus as we work to bring our sensors to patients. We are also building manufacturing capabilities to scale production.